Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.
Identifieur interne : 001399 ( Main/Exploration ); précédent : 001398; suivant : 001400Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.
Auteurs : Catherine Hodge [Royaume-Uni] ; Fiona Marra [Royaume-Uni] ; Catia Marzolini [Royaume-Uni, Suisse] ; Alison Boyle [Royaume-Uni] ; Sara Gibbons [Royaume-Uni] ; Marco Siccardi [Royaume-Uni] ; David Burger [Pays-Bas] ; David Back [Royaume-Uni] ; Saye Khoo [Royaume-Uni]Source :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (effets indésirables), Antiviraux (pharmacocinétique), Antiviraux (usage thérapeutique), Betacoronavirus (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Interactions médicamenteuses (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Traitements en cours d'évaluation (effets indésirables).
- MESH :
- effets indésirables : Antiviraux, Traitements en cours d'évaluation.
- pharmacocinétique : Antiviraux.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux.
- Betacoronavirus, Humains, Interactions médicamenteuses, Pandémies.
English descriptors
- KwdEn :
- Antiviral Agents (adverse effects), Antiviral Agents (pharmacokinetics), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Drug Interactions (MeSH), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH), Therapies, Investigational (adverse effects).
- MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , pharmacokinetics : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- adverse effects : Therapies, Investigational.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Drug Interactions, Humans, Pandemics, SARS-CoV-2.
Abstract
As global health services respond to the coronavirus pandemic, many prescribers are turning to experimental drugs. This review aims to assess the risk of drug-drug interactions in the severely ill COVID-19 patient. Experimental therapies were identified by searching ClinicalTrials.gov for 'COVID-19', '2019-nCoV', '2019 novel coronavirus' and 'SARS-CoV-2'. The last search was performed on 30 June 2020. Herbal medicines, blood-derived products and in vitro studies were excluded. We identified comorbidities by searching PubMed for the MeSH terms 'COVID-19', 'Comorbidity' and 'Epidemiological Factors'. Potential drug-drug interactions were evaluated according to known pharmacokinetics, overlapping toxicities and QT risk. Drug-drug interactions were graded GREEN and YELLOW: no clinically significant interaction; AMBER: caution; RED: serious risk. A total of 2378 records were retrieved from ClinicalTrials.gov, which yielded 249 drugs that met inclusion criteria. Thirteen primary compounds were screened against 512 comedications. A full database of these interactions is available at www.covid19-druginteractions.org. Experimental therapies for COVID-19 present a risk of drug-drug interactions, with lopinavir/ritonavir (10% RED, 41% AMBER; mainly a perpetrator of pharmacokinetic interactions but also risk of QT prolongation particularly when given with concomitant drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 27% AMBER, victims of some interactions due to metabolic profile but also perpetrators of QT prolongation) posing the greatest risk. With management, these risks can be mitigated. We have published a drug-drug interaction resource to facilitate medication review for the critically ill patient.
DOI: 10.1093/jac/dkaa340
PubMed: 32750131
PubMed Central: PMC7454591
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.</title>
<author><name sortKey="Hodge, Catherine" sort="Hodge, Catherine" uniqKey="Hodge C" first="Catherine" last="Hodge">Catherine Hodge</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marra, Fiona" sort="Marra, Fiona" uniqKey="Marra F" first="Fiona" last="Marra">Fiona Marra</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>University of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>University of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boyle, Alison" sort="Boyle, Alison" uniqKey="Boyle A" first="Alison" last="Boyle">Alison Boyle</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gibbons, Sara" sort="Gibbons, Sara" uniqKey="Gibbons S" first="Sara" last="Gibbons">Sara Gibbons</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Siccardi, Marco" sort="Siccardi, Marco" uniqKey="Siccardi M" first="Marco" last="Siccardi">Marco Siccardi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Burger, David" sort="Burger, David" uniqKey="Burger D" first="David" last="Burger">David Burger</name>
<affiliation wicri:level="3"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea>
<placeName><settlement type="city">Nimègue</settlement>
<region type="province" nuts="2">Gueldre</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Back, David" sort="Back, David" uniqKey="Back D" first="David" last="Back">David Back</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khoo, Saye" sort="Khoo, Saye" uniqKey="Khoo S" first="Saye" last="Khoo">Saye Khoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Royal Liverpool University Hospital, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Liverpool University Hospital, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32750131</idno>
<idno type="pmid">32750131</idno>
<idno type="doi">10.1093/jac/dkaa340</idno>
<idno type="pmc">PMC7454591</idno>
<idno type="wicri:Area/Main/Corpus">000F91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F91</idno>
<idno type="wicri:Area/Main/Curation">000F91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000F91</idno>
<idno type="wicri:Area/Main/Exploration">000F91</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.</title>
<author><name sortKey="Hodge, Catherine" sort="Hodge, Catherine" uniqKey="Hodge C" first="Catherine" last="Hodge">Catherine Hodge</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marra, Fiona" sort="Marra, Fiona" uniqKey="Marra F" first="Fiona" last="Marra">Fiona Marra</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>University of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>University of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boyle, Alison" sort="Boyle, Alison" uniqKey="Boyle A" first="Alison" last="Boyle">Alison Boyle</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gibbons, Sara" sort="Gibbons, Sara" uniqKey="Gibbons S" first="Sara" last="Gibbons">Sara Gibbons</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Siccardi, Marco" sort="Siccardi, Marco" uniqKey="Siccardi M" first="Marco" last="Siccardi">Marco Siccardi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Burger, David" sort="Burger, David" uniqKey="Burger D" first="David" last="Burger">David Burger</name>
<affiliation wicri:level="3"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea>
<placeName><settlement type="city">Nimègue</settlement>
<region type="province" nuts="2">Gueldre</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Back, David" sort="Back, David" uniqKey="Back D" first="David" last="Back">David Back</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khoo, Saye" sort="Khoo, Saye" uniqKey="Khoo S" first="Saye" last="Khoo">Saye Khoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Royal Liverpool University Hospital, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Liverpool University Hospital, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of antimicrobial chemotherapy</title>
<idno type="eISSN">1460-2091</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (pharmacokinetics)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Drug Interactions (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Therapies, Investigational (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (pharmacocinétique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Interactions médicamenteuses (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Traitements en cours d'évaluation (effets indésirables)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Therapies, Investigational</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
<term>Traitements en cours d'évaluation</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Drug Interactions</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Humains</term>
<term>Interactions médicamenteuses</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As global health services respond to the coronavirus pandemic, many prescribers are turning to experimental drugs. This review aims to assess the risk of drug-drug interactions in the severely ill COVID-19 patient. Experimental therapies were identified by searching ClinicalTrials.gov for 'COVID-19', '2019-nCoV', '2019 novel coronavirus' and 'SARS-CoV-2'. The last search was performed on 30 June 2020. Herbal medicines, blood-derived products and in vitro studies were excluded. We identified comorbidities by searching PubMed for the MeSH terms 'COVID-19', 'Comorbidity' and 'Epidemiological Factors'. Potential drug-drug interactions were evaluated according to known pharmacokinetics, overlapping toxicities and QT risk. Drug-drug interactions were graded GREEN and YELLOW: no clinically significant interaction; AMBER: caution; RED: serious risk. A total of 2378 records were retrieved from ClinicalTrials.gov, which yielded 249 drugs that met inclusion criteria. Thirteen primary compounds were screened against 512 comedications. A full database of these interactions is available at www.covid19-druginteractions.org. Experimental therapies for COVID-19 present a risk of drug-drug interactions, with lopinavir/ritonavir (10% RED, 41% AMBER; mainly a perpetrator of pharmacokinetic interactions but also risk of QT prolongation particularly when given with concomitant drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 27% AMBER, victims of some interactions due to metabolic profile but also perpetrators of QT prolongation) posing the greatest risk. With management, these risks can be mitigated. We have published a drug-drug interaction resource to facilitate medication review for the critically ill patient.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32750131</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>75</Volume>
<Issue>12</Issue>
<PubDate><Year>2020</Year>
<Month>12</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of antimicrobial chemotherapy</Title>
<ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.</ArticleTitle>
<Pagination><MedlinePgn>3417-3424</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkaa340</ELocationID>
<Abstract><AbstractText>As global health services respond to the coronavirus pandemic, many prescribers are turning to experimental drugs. This review aims to assess the risk of drug-drug interactions in the severely ill COVID-19 patient. Experimental therapies were identified by searching ClinicalTrials.gov for 'COVID-19', '2019-nCoV', '2019 novel coronavirus' and 'SARS-CoV-2'. The last search was performed on 30 June 2020. Herbal medicines, blood-derived products and in vitro studies were excluded. We identified comorbidities by searching PubMed for the MeSH terms 'COVID-19', 'Comorbidity' and 'Epidemiological Factors'. Potential drug-drug interactions were evaluated according to known pharmacokinetics, overlapping toxicities and QT risk. Drug-drug interactions were graded GREEN and YELLOW: no clinically significant interaction; AMBER: caution; RED: serious risk. A total of 2378 records were retrieved from ClinicalTrials.gov, which yielded 249 drugs that met inclusion criteria. Thirteen primary compounds were screened against 512 comedications. A full database of these interactions is available at www.covid19-druginteractions.org. Experimental therapies for COVID-19 present a risk of drug-drug interactions, with lopinavir/ritonavir (10% RED, 41% AMBER; mainly a perpetrator of pharmacokinetic interactions but also risk of QT prolongation particularly when given with concomitant drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 27% AMBER, victims of some interactions due to metabolic profile but also perpetrators of QT prolongation) posing the greatest risk. With management, these risks can be mitigated. We have published a drug-drug interaction resource to facilitate medication review for the critically ill patient.</AbstractText>
<CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hodge</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marra</LastName>
<ForeName>Fiona</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marzolini</LastName>
<ForeName>Catia</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Boyle</LastName>
<ForeName>Alison</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gibbons</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Siccardi</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burger</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Radboud University Medical Centre, Nijmegen, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Back</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khoo</LastName>
<ForeName>Saye</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Royal Liverpool University Hospital, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Antimicrob Chemother</MedlineTA>
<NlmUniqueID>7513617</NlmUniqueID>
<ISSNLinking>0305-7453</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004347" MajorTopicYN="Y">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D035703" MajorTopicYN="N">Therapies, Investigational</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32750131</ArticleId>
<ArticleId IdType="pii">5880570</ArticleId>
<ArticleId IdType="doi">10.1093/jac/dkaa340</ArticleId>
<ArticleId IdType="pmc">PMC7454591</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Ann Pharmacother. 2002 Jan;36(1):72-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11816263</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):242-247</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32246834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2011;16(2):249-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21447874</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 2018 Oct;57(10):1347-1354</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29453687</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CMAJ. 2007 Aug 14;177(4):357-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17698824</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Basic Clin Pharmacol Toxicol. 2013 Feb;112(2):132-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22900583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22391553</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Pharmacother. 2002 Apr;36(4):621-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11918509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Epidemiol. 2011 Apr;64(4):383-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21195583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Mar 23;12(3):e0173509</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28334018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Health Syst Pharm. 2017 Jun 15;74(12):888-892</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28596225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trials. 2020 Jul 29;21(1):688</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32727613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Acquir Immune Defic Syndr. 2006 May;42(1):52-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16639344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2020 Mar 19;15(3):e0230548</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Monaldi Arch Chest Dis. 2020 Mar 30;90(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32231348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 2018 Jul;84(7):1617-1619</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29663482</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Swiss Med Wkly. 2014 Jan 22;144:w13906</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24452338</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 1993 Jan;17(1):65-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8423043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J STD AIDS. 2014 Jun;25(7):532-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24352136</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2017 Oct 24;61(11):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28848011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J STD AIDS. 2019 Jun;30(7):718-722</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30975070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2008 Jan 1;46(1):146-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18171231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2019 Jan;105(1):219-228</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29696643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2005 Apr 15;40(8):1173-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15791519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2020 Oct 1;75(10):3084-3086</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32556272</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
</country>
<region><li>Gueldre</li>
</region>
<settlement><li>Nimègue</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Hodge, Catherine" sort="Hodge, Catherine" uniqKey="Hodge C" first="Catherine" last="Hodge">Catherine Hodge</name>
</noRegion>
<name sortKey="Back, David" sort="Back, David" uniqKey="Back D" first="David" last="Back">David Back</name>
<name sortKey="Boyle, Alison" sort="Boyle, Alison" uniqKey="Boyle A" first="Alison" last="Boyle">Alison Boyle</name>
<name sortKey="Boyle, Alison" sort="Boyle, Alison" uniqKey="Boyle A" first="Alison" last="Boyle">Alison Boyle</name>
<name sortKey="Gibbons, Sara" sort="Gibbons, Sara" uniqKey="Gibbons S" first="Sara" last="Gibbons">Sara Gibbons</name>
<name sortKey="Khoo, Saye" sort="Khoo, Saye" uniqKey="Khoo S" first="Saye" last="Khoo">Saye Khoo</name>
<name sortKey="Khoo, Saye" sort="Khoo, Saye" uniqKey="Khoo S" first="Saye" last="Khoo">Saye Khoo</name>
<name sortKey="Marra, Fiona" sort="Marra, Fiona" uniqKey="Marra F" first="Fiona" last="Marra">Fiona Marra</name>
<name sortKey="Marra, Fiona" sort="Marra, Fiona" uniqKey="Marra F" first="Fiona" last="Marra">Fiona Marra</name>
<name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
<name sortKey="Siccardi, Marco" sort="Siccardi, Marco" uniqKey="Siccardi M" first="Marco" last="Siccardi">Marco Siccardi</name>
</country>
<country name="Suisse"><noRegion><name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
</noRegion>
<name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
</country>
<country name="Pays-Bas"><region name="Gueldre"><name sortKey="Burger, David" sort="Burger, David" uniqKey="Burger D" first="David" last="Burger">David Burger</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001399 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001399 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32750131 |texte= Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32750131" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |